Accordingly, we used patient data from the NeoPalAna clinical trial, a single-arm phase II clinical trial evaluating the neoadjuvant use of palbociclib, with an anastrozole backbone, in clinical stage 2 or 3 ER + primary breast cancer [28]. This evidence concerns the gene ESR1 and breast carcinoma.